European Journal of Biomedical and Pharmaceutical Sciences

A PROSPECTIVE OBSERVATIONAL STUDY OF DRUG TREATMENT IN PATIENTS OF POST PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY

Kimberly J. Rodrigues* and Ian A. Pereira

ABSTRACT

Background: Percutaneous coronary intervention (PCI) is a part of the standard treatment for acute coronary syndromesalong with drug therapy. Study aimed to assessdrugs prescribed to post angioplasty patients at discharge, adverse effects profile and any alteration made to the drug list. Methods: A prospective observational study for a period of 6months was conducted in Cardiology unitof Goa Medical College and Hospital. Case records of the patients who underwent PTCAwere followed up at 1st, 3rd, and 6th monthand any adverse effects, alterations made to the drug list of patients (Post PCI) were noted.The data collected was analyzed using MS Excel and results expressed as counts and percentages. Results: 100 cases were included for the study, 80 patients followed up. The proportion of ACS was found to be higher in age group of 51-70 years (73.75%). All patients received dual anti-plateletalong with a cholesterol lowering agent as a part of the standardDAPT regimenfollowed by (53.33%) anti-hypertensives. Double dose regimen of P2Y12 inhibitor was continuedtill the 1st month post procedure. The (36.2%) adverse effects of drugs, mostly encountered with (79.3%) ACE-inhibitor. The most common side effect was dry-cough, followed byswelling of ankle. Conclusion: Post PTCA, patients are put on cocktail of drugs which should be continued for at least 12 months to get better outcome according to the ACC/AHA guidelines. Such follow-up studies may support or detect variations in standard therapy and rationalize the drug therapy in terms of adverse events.

Keywords: Acute coronary syndrome, Prospective observational studies, PTCA, DAPT, Standard protocol, adverse effects.